Should You Be Confident in Argenx SE' (ARGX) Long-Term Profit Cycle?

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, ending the period with double-digit year-to-date gains. In the quarter, the fund’s Investor Class fund ARTMX returned 8.80%, Advisor Class fund APDMX posted a return of 8.80%, and Institutional Class fund APHMX returned 8.83%, compared to a 2.78% return for the Russell Midcap Growth Index. The significant outperformance was led by holdings in the health care sector. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Artisan Mid Cap Fund highlighted stocks such as Argenx SE (NASDAQ:ARGX). Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company. The one-month return of Argenx SE (NASDAQ:ARGX) was 10.70%, and its shares gained 50.38% of their value over the last 52 weeks. On October 14, 2025, Argenx SE (NASDAQ:ARGX) stock closed at $812.95 per share, with a market capitalization of $149.06 billion.

Artisan Mid Cap Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its third quarter 2025 investor letter:

"Among our top contributors were Argenx SE (NASDAQ:ARGX), Insmed and Lattice Semiconductor. Argenx is a commercial-stage biotech company with a first-in-class autoimmune therapy, VYVGART®, approved for myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. Recent results confirmed VYVGART®’s strong growth, supported by the launch of a new subcutaneous formulation that allows patients to self-administer the drug. Argenx is also studying VYVGART® in multiple other autoimmune disorders. We remain confident in the company’s long-term profit cycle as it continues to differentiate itself through a business model rooted in novel biology, driving repeatable and commercially meaningful innovation."

Argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 53 hedge fund portfolios held Argenx SE (NASDAQ:ARGX) at the end of the second quarter, compared to 54 in the previous quarter. While we acknowledge the potential of Argenx SE (NASDAQ:ARGX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Argenx SE (NASDAQ:ARGX) and shared the list of best quality stocks to buy. Argenx SE (NASDAQ:ARGX) was Artisan Mid Cap Fund's performance detractor in the previous quarter. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.